Stay updated on Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page’s footer revision label was updated from v3.5.2 to v3.5.3, indicating a website/version release change rather than any modification to the clinical study information.SummaryDifference0.0%

- Check23 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check52 days agoChange DetectedSite revision label updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check67 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. It indicates a minor update to the page without changing the core study details or eligibility criteria.SummaryDifference0.0%

- Check88 days agoChange DetectedThe page now displays revision v3.4.2; the previous revision v3.4.1 has been removed.SummaryDifference0.0%

- Check95 days agoChange DetectedThe page now shows Revision: v3.4.1, replacing the previous Revision: v3.4.0.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page.